Registration Document

Overview

The report highlights Abivax's positive 2018 clinical progress with ABX464, including impressive phase 2a ulcerative-colitis results and positive ABX464-005 HIV results. It also records receipt of an €831,000 Bpifrance milestone payment for the RNP-VIR program. In addition, the company arranged a €20 million structured debt financing with Kreos Capital to support continued development.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2018
Period: Ends 31 December 2018
Publication date: 29 April 2019
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services